In a scathing report, a pair of non-governmental organizations accused the European pharmaceutical industry of “failing to meaningfully invest” resources in the Innovative Medicines Initiative — a widely touted public-private partnership — in areas where research is badly needed.

Instead, the industry steered so-called in-kind contributions — such as personnel and facilities — to projects that were more commercially profitable, rather than those focused on long-term preparedness for epidemics, neglected tropical diseases, and HIV/AIDS, among other issues. And the NGOs also argued that the IMI was “late” in addressing the spread of the Ebola virus.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy